| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Luteolin 7-sulfate targets the CREB and MITF-mediated signaling pathways. CREB is a transcription factor that regulates the expression of genes involved in melanin synthesis, including MITF. MITF is a master regulator of melanocyte development and melanin production. By modulating these pathways, Luteolin 7-sulfate reduces the expression of the TYR gene, which encodes tyrosinase, the key enzyme in melanin synthesis. This results in decreased melanin production.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Luteolin 7-sulfate attenuates TYR gene expression through the intervention of CREB and MITF-mediated signaling pathways. This leads to reduced melanin synthesis. The compound's activity is assessed in melanocyte cell lines, where it inhibits melanin production and tyrosinase activity. Its effects on CREB and MITF signaling are confirmed by measuring the phosphorylation and transcriptional activity of these factors.
|
| ln Vivo |
In vivo activity of Luteolin 7-sulfate has not been extensively characterized in the available literature. As a melanin synthesis inhibitor, the compound has potential applications in skin lightening and the treatment of hyperpigmentation disorders. However, detailed in vivo efficacy data, including animal models of pigmentation, are not extensively reported. The compound is primarily used as a research tool.
|
| Enzyme Assay |
In vitro assays for Luteolin 7-sulfate involve measuring its effects on melanin synthesis and tyrosinase activity. Melanocyte cell lines (e.g., B16F10 melanoma cells) are treated with the compound, and melanin content is measured spectrophotometrically. Tyrosinase activity is assessed by measuring the oxidation of L-DOPA to dopachrome. CREB and MITF signaling are assessed by Western blotting for phosphorylated CREB and MITF protein levels. TYR gene expression is measured by qPCR.
|
| Cell Assay |
Cellular assays for Luteolin 7-sulfate are conducted using melanocyte cell lines such as B16F10 melanoma cells. Cells are treated with varying concentrations of the compound for 48-72 hours. Melanin content is measured by solubilizing cells in NaOH and measuring absorbance at 405 nm. Tyrosinase activity is assessed by incubating cell lysates with L-DOPA and measuring absorbance at 475 nm. CREB phosphorylation and MITF expression are assessed by Western blotting. TYR gene expression is measured by qPCR. Cell viability is assessed using MTT or similar assays.
|
| Animal Protocol |
In vivo animal studies for Luteolin 7-sulfate are limited. For pigmentation studies, animal models such as guinea pig or mouse skin could be used. Animals would be treated with the compound via topical application at various doses. Skin pigmentation would be assessed visually or by measuring melanin content in skin biopsies. However, specific in vivo study protocols are not extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Luteolin 7-sulfate have not been extensively characterized. The compound has a molecular weight of 366.30 and a molecular formula of C1₅H10O₉S. The sulfate group enhances water solubility. The compound is typically stored at -20degC. Detailed PK parameters such as half-life, bioavailability, and volume of distribution are not reported in the available literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for Luteolin 7-sulfate are limited. The compound is not intended for human therapeutic use and is supplied for research purposes only. In cell-based assays, the compound is generally well-tolerated at concentrations used for melanin synthesis inhibition studies. The compound is derived from natural sources and is considered to have low toxicity. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Luteolin-7-sulfate is a type of flavonoid compound. It has been reported to exist in fuchsia, annatto, and other organisms with relevant data.
Luteolin 7-sulfate is a flavonoid sulfate from the marine plant Phyllospadix iwatensis that inhibits melanin synthesis by attenuating TYR gene expression through CREB and MITF-mediated signaling pathways. It has potential applications in skin lightening and the treatment of hyperpigmentation disorders. The compound is not an FDA-approved drug and has no clinical indications. It is available in high purity (≥97%) and is typically stored at -20degC. |
| Molecular Formula |
C15H10O9S
|
|---|---|
| Molecular Weight |
366.2995
|
| Exact Mass |
366.004
|
| CAS # |
56857-57-9
|
| PubChem CID |
14016780
|
| Appearance |
Light yellow to yellow solid
|
| LogP |
0.8
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
652
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NTLSJCCPWSJISD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10O9S/c16-9-2-1-7(3-10(9)17)13-6-12(19)15-11(18)4-8(5-14(15)23-13)24-25(20,21)22/h1-6,16-18H,(H,20,21,22)
|
| Chemical Name |
[2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxochromen-7-yl] hydrogen sulfate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~170.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7300 mL | 13.6500 mL | 27.3000 mL | |
| 5 mM | 0.5460 mL | 2.7300 mL | 5.4600 mL | |
| 10 mM | 0.2730 mL | 1.3650 mL | 2.7300 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
